Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patients characteristics

From: First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Number of patients n = 30
Years of age -- median (range) 64 (47-78)
Estrogen-receptor status -- no. (%)  
   Positive 26 (87%)
   Negative 4 (13%)
Progesterone-receptor status -- no. (%)  
   Positive 18 (60%)
   Negative 12 (40%)
HER2 status -- no. (%)  
   Positive 0 (0%)
   Negative 30 (100%)
Previous adjuvant chemotherapy -- no. (%)  
   None 3 (10%)
   Anthracycline 15 (50%)
   Anthracycline + Taxane 8 (27%)
   Vinorelbine 1 (3%)
Disease-free interval -- no. (%)  
   ≤ 24 mo 7 (23%)
   > 24 mo 23 (77%)
Extent of disease -- no. (%)  
   ≥ 3 sites 22 (73%)
   < 3 sites 8 (27%)
Location of disease -- no. (%)  
   Visceral 21 (70.%)
   Non Visceral 9 (30.%)
ECOG Status  
   0 7 (23%)
   1 22 (73%)